Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

RBC Capital Says This Dystrophy Stock 'Is Worth A Look'

  • RBC Capital says Edgewise Therapeutics Inc's (NASDAQ:EWTXinterim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD and Duchenne muscular dystrophy (DMD) studies.
  • The analysts believe stable patient NSAAs in October readout can potentially drive shares up 100% and further improve the setup into 2Q23 placebo-controlled randomized DMD readout and 2H23 placebo-controlled randomized BMD readout.
  • Safety continued to look clean with good tolerability, which we believe underscores a wide therapeutic window that can enable dosing of both BMD adults and adolescents, as well as DMD patients. 
  • Overall, the analyst continues to like the company given the encouraging clinical and preclinical data, experienced management team, and sufficient cash to reach major catalysts.
  • RBC believes Edgewise is worth a look, especially with DMD getting more spotlight.
  • Price Action: EWTX shares are up 5.95% at $7.84 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.